$TSVT News
Last published 1y ago
- 1y agoTSVT2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers SquibbBusiness WireAcquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 million U.S.
- 1y agoTSVT2seventy bio Reports Fourth Quarter and Full Year 2024 Financial ResultsBusiness WireEntered into definitive merger agreement to be acquired by Bristol Myers Squibb at a price of $5.00 per share in an all-cash transaction; expected to close in the second quarter of 2025 Abecma generated $242 million
- 1y agoBMYTSVT2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers SquibbBusiness Wire$5.00 per share, all-cash transaction Expected to close in the second quarter of 2025, subject to customary closing conditions 2seventy bio, Inc. (NASDAQ:TSVT), today announced a definitive merger agreement under
- 1y agoTSVT2seventy bio to Participate in the 2025 TD Cowen Healthcare ConferenceBusiness Wire2seventy bio, Inc. (NASDAQ:TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming TD Cowen 45th Annual Healthcare Conference on March 5, 2025 at 11:10 a.m. ET in
- 1y agoTSVT2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial ResultsBusiness Wire$242 million in U.S. Abecma sales in 2024 Approximately $184 million of cash, cash equivalents and marketable securities as of December 31, 2024 Net cash burn of $9 million in the fourth quarter of 2024; path to
- 1y agoTSVT2seventy bio, Inc. (TSVT) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoTSVT2seventy bio Reports Third Quarter Financial Results and Recent Operational ProgressBusiness WireAbecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in KarMMa-9 study results in over $80 million in anticipated cost savings
- 2y agoTSVT2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor ConferenceBusiness Wire2seventy bio, Inc. (NASDAQ:TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the financial
- 2y agoTSVT2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue PerformanceBusiness Wire2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study Decision results in over $80 million in anticipated cost savings for 2seventy over the next several years and accelerates path to
- 2y agoTSVT2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare ConferenceBusiness Wire2seventy bio, Inc. (NASDAQ:TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024 at
- 2y agoTSVT2seventy bio, Inc. (TSVT) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoTSVT2seventy bio Reports Second Quarter Financial Results and Recent Operational ProgressBusiness WireFollowing regulatory approval in the earlier line setting this quarter, Abecma generated $54 million U.S. commercial revenue and saw meaningful growth in demand Recent completion of Hemophilia A and gene editing
- 2y agoTSVT2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024Business Wire2seventy bio, Inc. (NASDAQ:TSVT) will announce its second quarter 2024 financial results on Wednesday, August 7, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference
- 2y agoTSVT2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 millionBusiness Wire- Divestiture Supports Company Focus on Development and Commercialization of Abecma - 2seventy bio, Inc. (NASDAQ:TSVT), announced today the completion of an asset purchase agreement ("APA") by Novo Nordisk. Under the
- 2y agoTSVT2seventy bio to Participate in Upcoming Investor ConferencesBusiness Wire2seventy bio, Inc. (NASDAQ:TSVT) announced today that members of the management team will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO
- 2y agoTSVT2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoTSVT2seventy bio Reports First Quarter Financial Results and Recent Operational ProgressBusiness WireU.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy; Commercial Launch Underway Completion of R&D Pipeline Divestiture to Regeneron Sets
- 2y agoTSVT2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024Business Wire2seventy bio, Inc. (NASDAQ:TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference
- 2y agoBMYTSVTU.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of TherapyBusiness WireAbecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile Expanded
- 2y agoTSVT2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to RegeneronBusiness Wire- Company Now Exclusively Focused on Development and Commercialization of Abecma - 2seventy bio, Inc. (NASDAQ:TSVT), announced today the completion of the asset purchase agreement ("APA") by Regeneron Pharmaceuticals,
- 2y agoTSVT2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of DirectorsBusiness Wire2seventy bio, Inc. (NASDAQ:TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new
- 2y agoBMYTSVTFDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of TherapyBusiness WireThe supplemental Biologics License Application for Abecma in this indication remains under review with the FDA; Abecma has been approved in Japan and Switzerland and received a positive CHMP Opinion by the European
- 2y agoTSVT2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational ProgressBusiness WireNew strategic path forward as Abecma-focused company announced in January 2024; on track to close Asset Sale of R&D pipeline to Regeneron in the first half of 2024 U.S. Food and Drug Administration Oncologic Drugs
- 2y agoTSVT2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor ConferencesBusiness Wire2seventy bio, Inc. (NASDAQ:TSVT) will announce its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Members of the management
- 2y agoTSVT2seventy bio to Participate in Upcoming Investor ConferencesBusiness Wire2seventy bio, Inc. (NASDAQ:TSVT), announced today that members of the management team will present at the following upcoming investor conferences: Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, the
- 2y agoBMYTSVTBristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 StudyBusiness WireBristol Myers Squibb (NYSE:BMY) and 2seventy bio, Inc. (NASDAQ:TSVT) today announced that a notice was published in the Federal Register that the U.S. Food and Drug Administration (FDA) will convene a virtual meeting of
- 2y agoTSVT2seventy bio Announces New Strategic Path ForwardBusiness Wire- Company to focus exclusively on commercialization and development of Abecma, in partnership with Bristol Myers Squibb - - Company to sell R&D pipeline to Regeneron to launch Regeneron Cell Medicines business led
- 2y agoBMYTSVTAbecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3Business WireAt median follow-up of more than 30 months, Abecma maintained a 51% reduction in risk of disease progression or death with median PFS of 13.8 months compared with 4.4 months for standard regimens Responses were
- 2y agoTSVT2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)Business Wire2seventy bio, Inc. (NASDAQ:TSVT), a leading immuno-oncology cell therapy company, announced today that the Company will host a conference call on Tuesday, December 12, 2023, at 8:00am ET. The event will highlight data
- 2y agoTSVT2seventy bio Reiterates Commitment to Maximizing Shareholder ValueBusiness Wire2seventy bio, Inc. (NASDAQ:TSVT), ("2seventy" or "the Company"), a leading immuno-oncology cell therapy company, today issued the following statement reiterating its commitment to maximizing shareholder value: As we
- 2y agoBLUETSVTEngine Capital Sends Letter to 2seventy's Board of Directors Outlining Steps to Maximize Shareholder ValueBusiness WireBelieves 2seventy Could Be Conservatively Worth ~$9 Per Share if the Company Exclusively Focuses on Its Most-Valuable Asset Abecma, Reduces Corporate Overhead and Makes Improvements to the Composition of the Management
- 2y agoBMYTSVTBristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple MyelomaBusiness WireBristol Myers Squibb (NYSE:BMY) and 2seventy bio, Inc. (NASDAQ:TSVT) today announced the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will meet to review data supporting the
- 2y agoTSVT2seventy bio, Inc. (TSVT) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoTSVT2seventy bio Reports Third Quarter Financial Results and Recent Operational ProgressBusiness WireAbecma (idecabtagene vicleucel) data to be presented at ASH 2023; multiple new analyses of KarMMa-3 and KarMMa-2c add to growing body of data supporting the potential safety and efficacy of Abecma in earlier lines of
- 3y agoTSVT2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023Business Wire2seventy bio, Inc. (NASDAQ:TSVT), a leading immune-oncology cell therapy company, will announce its third quarter 2023 financial results on Tuesday, November 14, 2023. 2seventy bio will host a conference call and
- 3y agoTSVTDeep Genomics Announces the Appointment of Brian O'Callaghan as CEOBusiness WireO'Callaghan, a well-regarded life-science business leader with global experience and a significant track record of success, joins as part of plan to evolve Deep Genomics as a forward-integrated biopharmaceutical
- 3y agoTSVT2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial RunwayBusiness WireApproximately 40% workforce reduction combined with related actions expected to achieve $130+ million savings in the 2024-2025 period; projected cash runway into at least 2026 to support focus on long-term
- 3y agoTSVT2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune TherapiesBusiness WireInitial MAGE-A4 T-cell collaboration program set to enter clinic ahead of schedule by end of 2023 Companies plan to add programs in oncology and autoimmune disease to collaboration 2seventy bio, Inc. (NASDAQ:TSVT),
- 3y agoTSVT2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare ConferenceBusiness Wire2seventy bio, Inc. (NASDAQ:TSVT), a leading immune-oncology cell therapy company, announced today that members of the management team will participate in a fireside chat at the upcoming 2023 Morgan Stanley Global
- 3y agoTSVT2seventy bio Reports Second Quarter Financial Results and Recent Operational ProgressBusiness WireAbecma (idecabtagene vicleucel) generated $115 million U.S. commercial revenue in 2Q 2023, supporting lower end of U.S. revenue guidance of $470-570 million 2seventy bio provides update on PLAT-08 study in AML with
- 3y agoTSVT2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023Business Wire2seventy bio, Inc. (NASDAQ:TSVT), a leading immune-oncology cell therapy company, will announce its second quarter 2023 financial results on Monday, August 14, 2023. 2seventy bio will host a conference call and webcast
- 3y agoTSVT2seventy bio to Participate in 2023 Wedbush PacGrow Healthcare ConferenceBusiness Wire2seventy bio, Inc. (NASDAQ:TSVT), a leading immune-oncology cell therapy company, announced today that members of the management team will present at the upcoming 2023 Wedbush PacGrow Healthcare Conference on August 8,
- 3y agoTSVT2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid LeukemiaBusiness Wire2seventy bio, Inc. (NASDAQ:TSVT), a leading immuno-oncology cell therapy company, today announced that the Phase 1 trial of the PLAT-08 study of SC-DARIC33 in Acute Myeloid Leukemia (AML) has been paused by Seattle
- 3y agoTSVT2seventy bio to Participate in Upcoming Investor ConferenceBusiness Wire2seventy bio, Inc. (NASDAQ:TSVT), a leading immuno-oncology cell therapy company, announced today that members of the management team will participate in a fireside chat at the upcoming Goldman Sachs 44th Annual Global
- 3y agoTSVT2seventy bio Presents Late-Breaking Results for SC-DARIC33, an Investigational CD33-Targeting CAR T in Pediatric and Young Adults with Relapsed or Refractory Acute Myeloid LeukemiaBusiness WireResults of preliminary correlative analysis from the PLAT-08 study show rapamycin-regulated in vivo expansion and activation of SC-DARIC33 T cells as well as concurrent anti-CD33 activity Enhanced anti-acute myeloid
- 3y agoTSVT2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies PortfolioBusiness WirebbT369, a dual-targeted (CD79a/CD20) and CBLB gene edited autologous CAR T for non-Hodgkin lymphoma, showed edit-driven enhanced T cell activity in multiple preclinical models RESET, a novel TCR coupled antigen
- 3y agoTSVT2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023Business WireSubgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma (RRMM) from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from KarMMa-3 study of
- 3y agoTSVT2seventy bio Reports First Quarter Financial Results and Recent Operational ProgressBusiness WireAbecma (idecabtagene vicleucel) generated $118 million U.S. commercial revenue in 1Q 2023, supporting upper end of U.S. revenue guidance of $470-570 million U.S. FDA accepted supplemental Biologics License Application
- 3y agoTSVT2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual MeetingBusiness WireLate-breaking oral presentation will show early findings from Phase I PLAT-08 study of SC-DARIC33, an investigational, potentially first-in-class CD33-targeting CAR T in pediatric and young adults with
- 3y agoTSVT2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A ProgramBusiness Wire2seventy bio plans to present data at virtual Research and Development deep dive on May 19, 2023 2seventy bio, Inc. (NASDAQ:TSVT) a leading immuno-oncology cell therapy company, today announced that it has achieved a